Aim/hypothesis This study aimed to investigate the safety and efficacy of treatment with
allogeneic Wharton's jelly-derived mesenchymal stromal cells (MSCs) in recent-onset type 1 …

Background The preservation or restoration of β cell function in type 1 diabetes (T1D)
remains as an attractive and challengeable therapeutic target. Mesenchymal stromal cells …

OBJECTIVE To determine the safety and effects on insulin secretion of umbilical cord (UC)
mesenchymal stromal cells (MSCs) plus autologous bone marrow mononuclear cell (aBM …

1) Stem Cell Research Center, the Affiliated Hospital of Medical College, Qingdao
University, Qingdao 266003, China 2) Endocrinology Department, the Affiliated Hospital of …

Background To determine the efficacy and safety of umbilical cord-derived mesenchymal
stem cells (UC-MSCs) in Chinese adults with type 2 diabetes mellitus (T2DM). Methods In …

Background aims To explore the long-term safety and benefit of umbilical cord
mesenchymal stromal cell (MSCs) plus autologous bone marrow mononuclear cell (aBM …

Introduction Post‐partum umbilical cord Wharton Jelly‐derived adult mesenchymal stem
cells (hUCMS) hold anti‐inflammatory and immunosuppressive properties. Human …

Background Stem cell therapy provides great hope for patients with diabetes mellitus (DM).
DM is a seriously alarming metabolic disease characterized by hyperglycemia and β cell …

Abstract Type 2 diabetes (T2D) is characterized by progressive and inexorable β‑cell
dysfunction, leading to insulin deficiency. Novel strategies to preserve the remaining β‑cells …

BACKGROUND Progressive pancreatic β-cell dysfunction is a fundamental part of the
pathology of type 2 diabetes mellitus (T2DM). Cellular therapies offer novel opportunities for …